4 September 2023
Gendius receives UKCA mark for CKD Screen Prioritizer
British health data start-up Gendius has received a UKCA mark for its digital pre-screening technology, the CKD Screening Prioritizer (CSP). The CSP, which is now a registered medical device in the UK, uses readily available data to predict whether a patient is likely to be...
22 August 2023
Infex receives approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it has received approval to commence dosing the final Phase Ia cohort of healthy volunteers and to proceed to dosing the first cohort in the first-in-patient Phase IIa dose-ranging...
16 August 2023
Infex Therapeutics - Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate … • COV-X outperforms Pfizer’s approved antiviral in a pre-clinical mouse SARS-CoV-2 efficacy trial … • Unlike many competitors, COV-X blocks a unique key protein and has potential for broad...
5 July 2023
Oxford BioTherapeutics initiates Phase Ib clinical trial for OBT076 in patients with advanced solid tumours
… • OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumours by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab. • The Phase Ib combination study for OBT076 builds on previous...
29 June 2023
CPI Enterprises to help fund innovative medical device for brain tumours
CPI Enterprises have invested in a medical device which could dramatically increase long-term survival for people with the most common and aggressive type of brain tumours. This is CPI Enterprises’ ninth investment and fourth in the last 12 months. … QV Bioelectronics, based at...
15 June 2023
AI influencer tackles TikTok health trend
Alderley Park, Cheshire, UK – 10th June 2023 Contraceptive pill brand, Lovima® has created an AI influencer to help educate young women about hormonal contraception in response to the latest TikTok health trend. #gettingoffbirthcontrol has over nine million views on TikTok, and...
5 June 2023
Cytox brings ground-breaking genetic risk test for Alzheimer's disease to the UK
1st June 2023 - There are currently around 900,000 people in the UK living with dementia, and this number is expected to rise to over 1 million by 2025. Alzheimer's disease (AD) is the most common type of dementia in the UK, accounting for around two-thirds of all cases. Today...
25 May 2023
Oxford BioTherapeutics and Boehringer Ingelheim agree on extension to second multi-year collaboration in cancer immunology
Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced that it has extended its second multi-year collaboration with...
16 May 2023
Study by Healum demonstrates its platform improves health outcomes for diabetes patients
A randomised control study to explore the impact and efficacy of the Healum Collaborative Care planning Software and App on condition management for Type 2 diabetes (T2D) patients in NHS primary care has produced promising results that have been shown to improve health outcomes.
20 April 2023
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC
• Trial will investigate OBT076 as monotherapy and in sequence with balstilimab … • CD205, OBT076’s target antigen , is overexpressed in ~ 80 % of ACC tumor biopsy samples … • Recur r ent or metastatic ACC patients currently face poor prognosis and very few treatment ...